Methotrexate (MTX) is an antimetabolite and antifolate drug currently used in the treatment of cancer, autoimmune diseases, ectopic pregnancy, and for the induction of medical abortions. Methotrexate competitively inhibits dihydrofolate reductase (DHFR), an enzyme that participates in the tetrahydrofolate synthesis. MTX immunotoxins have been shown to remove MCF-7 cells in culture and have been suggested as a potential candidate for the treatment of MTX-responsive cancers.
Methotrexate-SAP eliminates cells expressing DHFR.
The following control is recommended for validating the specificity of the beta conjugate: Blank-SAP (Cat. #IT-21).
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.